STOCK PURCHASE AGREEMENTStock Purchase Agreement • November 2nd, 2018 • Vifor (International) LTD • Pharmaceutical preparations • New York
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of September 17, 2018, by and between Glaxo Group Limited, a limited company organized under the laws of England and Wales, with registered seat at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (“Seller”), and Vifor (International) Ltd., a limited company organized under the laws of Switzerland, with residence at Rechenstrasse 21, 9014 St. Gallen, Switzerland (“Purchaser”). Seller and Purchaser may each be referred to herein singly as a “Party”, and collectively as the “Parties.”
Exhibit B JOINT FILING AGREEMENTJoint Filing Agreement • October 23rd, 2020 • Vifor (International) LTD • Pharmaceutical preparations
This Joint Filing Agreement, dated as of October 23, 2020, is made by and between Vifor (International) Ltd., an entity formed under the laws of Switzerland, Vifor Pharma Ltd., an entity formed under the laws of Switzerland, and Vifor Fresenius Medical Care Renal Pharma Ltd., an entity formed under the laws of Switzerland. The foregoing are collectively referred to herein as the “Parties” and each individually as a “Party.” Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, the Parties hereby acknowledge and agree that the Schedule 13G is filed on behalf of each such Party and that all subsequent amendments to the Statement on Schedule 13G shall be filed on behalf of each of the Parties without the necessity of filing additional joint acquisition statements. The Parties hereby acknowledge that each Party shall be responsible for timely filing of such amendments, and for the completeness and accuracy of the information concerning such Pa
10b5-1 SALE PLAN AGREEMENT10b5-1 Sale Plan Agreement • July 16th, 2020 • Vifor (International) LTD • Pharmaceutical preparations • New York
This letter agreement (this “Letter Agreement”) confirms the terms and conditions under which Vifor (International) Ltd, an entity formed under the laws of Switzerland (the “Seller”), hereby establishes a plan (the “Plan”) to sell shares of common stock, par value $$0.001 (the “Securities”), of Chemocentryx, Inc. (the “Issuer”), and under which J.P. Morgan Securities LLC (“JPMS”) will act as its exclusive agent to execute the Plan.
AGREEMENTShareholder Agreement • November 2nd, 2018 • Vifor (International) LTD • Pharmaceutical preparations • Delaware
This Agreement (this “Agreement”) is made and entered into as of September 17, 2018, by and among the persons and entities listed on Schedule A hereto (each, individually, a “Vifor Entity” and collectively, the “Vifor Entities”) and ChemoCentryx, Inc., a Delaware corporation (the “Company”).
JOINT FILING AGREEMENTJoint Filing Agreement • November 2nd, 2018 • Vifor (International) LTD • Pharmaceutical preparations
This Joint Filing Agreement, dated as of November 1, 2018, is made by and between Vifor (International) Ltd., an entity formed under the laws of Switzerland, Vifor Pharma Ltd., an entity formed under the laws of Switzerland, and Vifor Fresenius Medical Care Renal Pharma Ltd., an entity formed under the laws of Switzerland. The foregoing are collectively referred to herein as the “Parties” and each individually as a “Party.” Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, the Parties hereby acknowledge and agree that the Schedule 13D is filed on behalf of each such Party and that all subsequent amendments to the Statement on Schedule 13D shall be filed on behalf of each of the Parties without the necessity of filing additional joint acquisition statements. The Parties hereby acknowledge that each Party shall be responsible for timely filing of such amendments, and for the completeness and accuracy of the information concerning such Pa
Exhibit B JOINT FILING AGREEMENTJoint Filing Agreement • July 25th, 2023 • Vifor (International) LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • October 30th, 2024 • Vifor (International) LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.
